ACTA1 and systemic sclerosis: Treatment with ATO 2.5 μg/g + CuCl2 decreased by 70% the expression of α-SMA (p<0.0001) and by 85% the expression of collagen I (p<0.0001), compared to the HOCl-SSc-mice.